MRVI vs. XENE, GMTX, IBRX, TWST, ARWR, APLS, VCEL, RXRX, NAMS, and DNLI
Should you be buying Maravai LifeSciences stock or one of its competitors? The main competitors of Maravai LifeSciences include Xenon Pharmaceuticals (XENE), Gemini Therapeutics (GMTX), ImmunityBio (IBRX), Twist Bioscience (TWST), Arrowhead Pharmaceuticals (ARWR), Apellis Pharmaceuticals (APLS), Vericel (VCEL), Recursion Pharmaceuticals (RXRX), NewAmsterdam Pharma (NAMS), and Denali Therapeutics (DNLI). These companies are all part of the "pharmaceutical products" industry.
Maravai LifeSciences vs. Its Competitors
Maravai LifeSciences (NASDAQ:MRVI) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, institutional ownership, risk, dividends, media sentiment, valuation and profitability.
In the previous week, Maravai LifeSciences had 3 more articles in the media than Xenon Pharmaceuticals. MarketBeat recorded 7 mentions for Maravai LifeSciences and 4 mentions for Xenon Pharmaceuticals. Xenon Pharmaceuticals' average media sentiment score of 0.30 beat Maravai LifeSciences' score of 0.26 indicating that Xenon Pharmaceuticals is being referred to more favorably in the news media.
Maravai LifeSciences has a beta of 0.28, meaning that its stock price is 72% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.1, meaning that its stock price is 10% more volatile than the S&P 500.
50.3% of Maravai LifeSciences shares are held by institutional investors. Comparatively, 95.5% of Xenon Pharmaceuticals shares are held by institutional investors. 2.1% of Maravai LifeSciences shares are held by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Maravai LifeSciences has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Maravai LifeSciences, indicating that it is currently the more affordable of the two stocks.
Maravai LifeSciences currently has a consensus price target of $6.64, suggesting a potential upside of 140.54%. Xenon Pharmaceuticals has a consensus price target of $54.82, suggesting a potential upside of 67.74%. Given Maravai LifeSciences' higher possible upside, analysts plainly believe Maravai LifeSciences is more favorable than Xenon Pharmaceuticals.
Xenon Pharmaceuticals has a net margin of 0.00% compared to Maravai LifeSciences' net margin of -67.14%. Maravai LifeSciences' return on equity of -12.91% beat Xenon Pharmaceuticals' return on equity.
Summary
Maravai LifeSciences and Xenon Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.
Get Maravai LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRVI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding MRVI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Maravai LifeSciences Competitors List
Related Companies and Tools
This page (NASDAQ:MRVI) was last updated on 7/10/2025 by MarketBeat.com Staff
Free MRVI Stock Alerts